merck glp 1 drug The discovery and development of GLP-1 based drugs that have revolutionized the treatment of obesity GLP-1 Agonists: A Comprehensive Overview

In our earlier GLP-1 Insight Drop, we showed how the 2021 approval of Wegovy catalyzed a step-change in metabolic R&Dso much so that GLP-1 programs now account for 159 out of 426 active metabolic programs (~40%), effectively lifting the entire category

doi: 10.1128/aem.57.2.549-552.1991 35 EriksenG

Glucocorticoid receptor antagonization propels endogenous cardiomyocyte proliferation and cardiac regeneration

oral formulations serve those valuing simplicity and flexibility

Your well-being deserves nothing less

They work at complementary levels: Epitalon addresses chromatin structure and telomere biology, while GHK-Cu resets gene expression patterns across thousands of genes